Pharma BD Deal Intelligence
Angelini's $4.1B all-cash entry into the U.S. market buys Catalyst's FIRDAPSE, AGAMREE, and FYCOMPA at a 21% premium, backed by Blackstone co-investment, with a $155.5 million termination fee underscoring how tightly the deal is bound to closing.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results. Full Year 2024 Total Revenues of $491.7 Million, Marking Another…
Angelini to buy Catalyst in $4B play for rare neuro drugs. The acquisition reflects broader pharma momentum in CNS therapeutics, with multiple major players…
Catalyst Pharmaceuticals, Inc. announced that it entered into a definitive merger agreement with Angelini Pharma S.p.A. under which Angelini Pharma agreed to…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Angelini Pharma agreed to acquire all outstanding shares of Catalyst Pharmaceuticals for $31.50 per share in cash, a total equity value of approximately $4.1 billion (€3.5 billion). The price is a 21% premium to Catalyst's unaffected April 22, 2026 closing price (28% vs. its 30-day VWAP). The all-cash deal is structured as a one-step merger (via Angelini Cielo Inc.) subject to a Catalyst stockholder vote and HSR antitrust clearance, with an expected close in Q3 2026; there is no financing condition. The acquisition marks Angelini's entry into the U.S. market and adds Catalyst's commercial rare-neurological franchise (FIRDAPSE, AGAMREE, FYCOMPA) to Angelini's brain-health platform. Financing is via cash and debt, with BNP Paribas as sole global coordinator/underwriter and Blackstone funds participating as co-investors. A Catalyst termination fee of approximately $155.5 million applies in specified circumstances. Concurrent with the deal, Catalyst settled its last FIRDAPSE generic patent litigation (with Hetero), pushing generic amifampridine entry no earlier than January 2035 and reinforcing the durability of its lead franchise.
3.4M US cases/yr · $137M FYCOMPA FY2024 US net product revenue
Epilepsy affects ~3.4 million Americans with ~30% of patients remaining drug-resistant despite multiple ASMs. FYCOMPA (perampanel) targets postsynaptic AMPA glutamate receptors, providing a mechanistically differentiated option for adjunctive use in focal and PGTC seizures. Patent exclusivity expired in 2025, exposing the asset to generic competition.
FYCOMPA operates in the crowded adjunctive epilepsy ASM market against UCB's Vimpat/Briviact, Jazz's Xyrem/Epidiolex, SK Life Science's Xcopri, and a deep generic AED bench. The asset is on a generic erosion curve post-2025 LOE, making the FYCOMPA contribution to Angelini's deal economics declining and the FIRDAPSE/AGAMREE durability the core thesis.
12K US cases/yr · $46M AGAMREE FY2024 US net product revenue (launched March 2024)
DMD is an X-linked recessive disorder caused by loss-of-function mutations in the dystrophin gene, leading to progressive muscle degeneration, loss of ambulation typically in the early teens, and cardiorespiratory failure. Corticosteroids remain the backbone of supportive therapy; AGAMREE (vamorolone) is a dissociative steroid designed to preserve efficacy with reduced bone/growth toxicity.
DMD therapeutics is a fragmented and crowded market spanning corticosteroids (deflazacort/Emflaza, prednisone), exon-skipping antisense oligos (Sarepta's Exondys 51/Vyondys 53/Amondys 45), Sarepta's gene therapy Elevidys, and PTC's Translarna (EU). AGAMREE competes primarily against deflazacort and prednisone on tolerability rather than disease modification.
1K US cases/yr · $306M FIRDAPSE FY2024 US net product revenue
LEMS is an ultra-rare autoimmune disorder in which antibodies against P/Q-type voltage-gated calcium channels at the neuromuscular junction impair acetylcholine release, producing proximal muscle weakness, areflexia, and autonomic dysfunction. ~50-60% of cases are paraneoplastic (most commonly SCLC); the remainder are idiopathic.
FIRDAPSE (amifampridine) is the only FDA-approved LEMS therapy in the US, with Jacobus Pharmaceuticals' Ruzurgi (also amifampridine) blocked from adult labeling after patent litigation. Off-label 3,4-diaminopyridine compounded use remains a residual competitive threat. Catalyst's LEMS franchise is effectively a monopoly subject only to authorized-generic risk near patent expiry.
Concurrent with the Angelini deal, Catalyst/SERB settled the final FIRDAPSE (amifampridine) ANDA litigation with Hetero before the scheduled May 18, 2026 trial; Hetero generic entry no earlier than January 2035. Reinforces the lead-asset exclusivity underpinning the $4.1B valuation.
Catalyst filed its preliminary merger proxy for the one-step merger with Angelini (via Angelini Cielo Inc.). Closing conditioned on a majority stockholder vote and HSR Act clearance; special meeting not yet held; expected close Q3 2026. Deal remains pending.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Angelini Pharma S.p.A. / Catalyst Pharmaceuticals, Inc. (this deal) | 2026 | $4.1B | — |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) | 2015 | $250M | 91 |
| Cephalon Inc. / Laboratoire L. Lafon S.A. (Group Lafon) | 2000 | $450M | 89 |
| Teva Pharmaceutical Industries Ltd. / Auspex Pharmaceuticals | 2015 | $3.5B | 86 |
| Teva Pharmaceutical Industries Ltd. / Biogal Pharmaceutical | 1995 | — | 82 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
← Browse all deals · How we score deals
More: 2026 deals · Neurology deals